AKT1 and breast carcinoma: Triciribine, an inhibitor of Akt phosphorylation and activation, reduces CSC population in T-cell acute lymphoblastic leukemia cells (Evangelisti et al., 2011) and human breast cancer cells SKBR3 cells (Jain et al., 2015).